Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.

被引：0
|
作者：
Ward, TH
Danson, S
Dawson, M
McGrath, H
Denneny, O
Cummings, J
Dive, C
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[3] Canc Res UK, Drug Dev Off, London, England
来源：
BRITISH JOURNAL OF CANCER | 2004年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [1] Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1
    Danson, S. J.
    Johnson, P.
    Ward, T. H.
    Dawson, M.
    Denneny, O.
    Dickinson, G.
    Aarons, L.
    Watson, A.
    Jowle, D.
    Cummings, J.
    Robson, L.
    Halbert, G.
    Dive, C.
    Ranson, M.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (07) : 1653 - 1660
  • [2] Final results of a phase I clinical trial of the bioreductive drug RH1
    Danson, S.
    Johnson, P.
    Ward, T.
    Dawson, M.
    Denneny, O.
    Watson, A.
    Jowle, D.
    Sharpe, P.
    Dive, C.
    Ranson, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH1.
    Danson, S
    Johnson, P
    Ward, T
    Dawson, M
    Denneny, O
    Cummings, J
    Jowle, D
    Howard, E
    Dive, C
    Ranson, M
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9150S - 9150S
  • [4] Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial
    Danson, S.
    Ranson, M.
    Denneny, O.
    Cummings, J.
    Ward, T. H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (06) : 851 - 861
  • [5] Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial
    S. Danson
    M. Ranson
    O. Denneny
    J. Cummings
    T. H. Ward
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 60 : 851 - 861
  • [6] A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
    Tate, Sonya C.
    Sykes, Amanda K.
    Kulanthaivel, Palaniappan
    Chan, Edward M.
    Turner, P. Kellie
    Cronier, Damien M.
    [J]. CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 335 - 344
  • [7] A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
    Sonya C. Tate
    Amanda K. Sykes
    Palaniappan Kulanthaivel
    Edward M. Chan
    P. Kellie Turner
    Damien M. Cronier
    [J]. Clinical Pharmacokinetics, 2018, 57 : 335 - 344
  • [8] Phase I clinical and pharmacokinetic trial of irofulven
    Thomas, JP
    Arzoomanian, R
    Alberti, D
    Feierabend, C
    Binger, K
    Tutsch, KD
    Steele, T
    Marnocha, R
    Smith, C
    Smith, S
    MacDonald, J
    Wilding, G
    Bailey, H
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (06) : 467 - 472
  • [9] Phase I clinical and pharmacokinetic trial of irofulven
    James P. Thomas
    Rhoda Arzoomanian
    Dona Alberti
    Chris Feierabend
    Kimberly Binger
    Kendra D. Tutsch
    Thomas Steele
    Rebecca Marnocha
    Charlotte Smith
    Sheri Smith
    John MacDonald
    George Wilding
    Howard Bailey
    [J]. Cancer Chemotherapy and Pharmacology, 2001, 48 : 467 - 472
  • [10] RH1, pre-clinical studies
    Hargreaves, RHJ
    Winski, SL
    Ross, D
    Alley, M
    Sausville, EA
    McGown, AT
    Butler, J
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 : 95 - 95
12345